PIK3CA Mutations Linked to Poor Survival in Early Appendiceal Cancer
Publication Title: PIK3CA Mutations in Early-Onset Appendiceal Adenocarcinoma
Summary
- Question
- This study examined the genetic differences between early-onset appendiceal adenocarcinoma (EOAC), diagnosed in patients under 50 years old, and late-onset appendiceal adenocarcinoma (LOAC), diagnosed in patients 50 years or older. The researchers specifically investigated the prevalence of PIK3CA mutations and their association with survival outcomes in these groups.
- Why it Matters
- Appendiceal adenocarcinoma is a rare cancer with distinct features based on the age of onset. Understanding molecular differences between EOAC and LOAC can help identify specific genetic markers, such as PIK3CA mutations, that influence prognosis and treatment outcomes. These insights are important for tailoring therapies and improving survival rates, particularly as EOAC cases are increasing among younger populations.
- Methods
- The researchers conducted a retrospective analysis using genomic data from 200 patients with appendiceal adenocarcinoma. Patients were divided into EOAC (under 50 years old) and LOAC (50 years or older) groups based on age at surgery. Genetic profiles were analyzed using sequencing data from the Memorial Sloan Kettering MetTropism database and validated with the AACR GENIE database. Statistical models assessed mutation prevalence and survival associations.
- Key Findings
- PIK3CA mutations were significantly more common in EOAC than LOAC, occurring in 17.1% of EOAC cases compared to 7.7% of LOAC cases. These mutations were exclusively observed in patients with metastatic disease and were linked to worse overall survival. Patients with PIK3CA mutations had a lower 3-year survival probability (41%) compared to those without the mutation (72%).
- Implications
- The findings highlight PIK3CA mutation status as a critical prognostic marker in appendiceal adenocarcinoma. Incorporating molecular profiling into treatment planning could help identify high-risk patients and guide the development of targeted therapies, such as PI3K inhibitors, to improve outcomes, particularly for EOAC patients.
- Next Steps
- The authors suggest further research to explore the functional role of PIK3CA mutations in appendiceal tumor development and evaluate the clinical effectiveness of PI3K-targeted therapies in this cancer type. They also recommend expanding studies to include diverse populations and early-stage tumors to validate findings.
- Funding Information
- This research was supported by grants from the National Medical Research Council (NMRC). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Yale University also provided funding and support for this research.
Full Citation
Gupta P, Gujarathi R, Qiao L, Godfrey E, Schultz K, Butensky S, Bader J, Sundar R, Cecchini M, Shergill A, Sheltzer J, Turaga K. PIK3CA Mutations in Early-Onset Appendiceal Adenocarcinoma. JCO Precision Oncology 2026, 10: e2500741. PMID: 41712872, DOI: 10.1200/po-25-00741.
This AI-assisted summary has been reviewed and approved by at least one of the study's authors to ensure it accurately reflects the research.
Authors
Princy Gupta
First AuthorKiran Turaga, MD, MPH
Last AuthorProfessor of Surgery (Oncology)
Additional Yale School of Medicine Authors
Other Authors
Research Themes
Keywords
Concepts
- Associated with worse OS;
- Appendiceal cancer;
- Appendiceal adenocarcinoma;
- Overall survival;
- Mutation profiles;
- Multivariate Cox proportional hazards model;
- Kaplan-Meier survival analysis;
- Time of surgery;
- Associated with survival;
- Cox proportional hazards models;
- Proportional hazards model;
- Late-onset disease;
- Metastatic disease;
- Mucinous tumors;
- PIK3CA mutations;
- Mutation status;
- Prognostic assessment;
- Retrospective analysis;
- Multivariate analysis;
- Adenocarcinoma;
- Therapeutic strategies;
- Patients;
- Survival analysis;
- Hazards model;
- Demographic features